TY - JOUR
T1 - In vivo effects of IL-4, IL-10, and amifostine on cytokine production in patients with acute myelogenous leukemia
AU - Tao, M.
AU - Li, Biaoru
AU - Nayini, J.
AU - Sivaraman, S.
AU - Song, S.
AU - Larson, A.
AU - Toofanfard, M.
AU - Chen, H.
AU - Venugopal, P.
AU - Preisler, H. D.
N1 - Funding Information:
This work was supported by the National Cancer Institute Grand 1-PO-01C A 7560641.
PY - 2001
Y1 - 2001
N2 - Both IL-4 and IL-10 have been shown in vitro to inhibit leukemia cell secretion of IL-1β, GM-CSF, and TNFα, and increase leukemia cell release of IL-1ra. In this study, we have investigated the in vivo effects of IL-4, IL-10, and amifostine on cytokine production in patients with acute myelogenous leukemia (AML). Serum IL-1ra, IL-1β, TNFα, GM-CSF, and SCF levels were measured in AML patients who received IL-4, IL-10, or amifostine. No significant changes in the serum levels of IL-1ra, IL-1β, TNFα, GM-CSF, and SCF were found in AML patients who received amifostine. Both IL-4 and IL-10 were found to increase serum IL-1ra. This data is in accord with the in vitro studies. However, IL-4 increased serum GM-CSF levels and IL-10 increased serum IL-1β and TNFα levels. These in vivo effects of the two cytokines differ from their in vitro effects. Despite the similar effects of IL-4 and IL-10 on cytokine production by AML cells in vitro, different effects were observed in AML patients in vivo. IL-4 increased serum SCF levels, whereas IL-10 decreased serum SCF levels. IL-4 increased serum GM-CSF levels, whereas IL-10 had no effect on them. Although IL-10 increased serum IL-1β and TNFα levels, IL-4 had no effect on them. These findings indicate that the in vitro effects of IL-4 and IL-10 do not necessarily reflect their in vivo effects, and that the complex effects of the two cytokines on serum cytokine levels make it difficult to predict their therapeutic potential.
AB - Both IL-4 and IL-10 have been shown in vitro to inhibit leukemia cell secretion of IL-1β, GM-CSF, and TNFα, and increase leukemia cell release of IL-1ra. In this study, we have investigated the in vivo effects of IL-4, IL-10, and amifostine on cytokine production in patients with acute myelogenous leukemia (AML). Serum IL-1ra, IL-1β, TNFα, GM-CSF, and SCF levels were measured in AML patients who received IL-4, IL-10, or amifostine. No significant changes in the serum levels of IL-1ra, IL-1β, TNFα, GM-CSF, and SCF were found in AML patients who received amifostine. Both IL-4 and IL-10 were found to increase serum IL-1ra. This data is in accord with the in vitro studies. However, IL-4 increased serum GM-CSF levels and IL-10 increased serum IL-1β and TNFα levels. These in vivo effects of the two cytokines differ from their in vitro effects. Despite the similar effects of IL-4 and IL-10 on cytokine production by AML cells in vitro, different effects were observed in AML patients in vivo. IL-4 increased serum SCF levels, whereas IL-10 decreased serum SCF levels. IL-4 increased serum GM-CSF levels, whereas IL-10 had no effect on them. Although IL-10 increased serum IL-1β and TNFα levels, IL-4 had no effect on them. These findings indicate that the in vitro effects of IL-4 and IL-10 do not necessarily reflect their in vivo effects, and that the complex effects of the two cytokines on serum cytokine levels make it difficult to predict their therapeutic potential.
KW - Acute myelogenous leukemia
KW - Amifostine
KW - IL-10
KW - IL-4,
KW - Serum cytokine levels
UR - http://www.scopus.com/inward/record.url?scp=0035075992&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035075992&partnerID=8YFLogxK
U2 - 10.3109/10428190109057966
DO - 10.3109/10428190109057966
M3 - Article
C2 - 11342369
AN - SCOPUS:0035075992
SN - 1042-8194
VL - 41
SP - 161
EP - 168
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 1-2
ER -
